Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver

Phase 2

Recruiting

• Conditions: on-alcoholic fatty liver.; Metabolic disorder, unspecified; E88.9

• Registration Number: IRCT20210412050944N2
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Patients who are between 5 to 15 years old.
Patients who have increased their liver enzymes more than 40 units per liter.
Patients who have been diagnosed with fatty liver in ultrasound.
Patients who have been diagnosed with non-alcoholic fatty liver disease by pediatric gastroenterology specialist.
Patients who parents consent to participate in this plan.

Exclusion Criteria

Patients who suffering from viral hepatitis.
Patients who suffering from diabetes.
Patients who have taken drugs affecting liver tests in the last 2 months.
Patients who suffering from hemochromatosis.
Patients who suffering from cirrhosis.
Patients who who suffering from addicted to alcohol
Patients who suffering from infectious diseases.
Patients who suffering from hypothyroidism.
Patients who are allergic to curcumin or L-carnitine.
Patients who suffering from hypothyroidism.
Patients who have not completed the medication for 3 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of children with non-alcoholic fatty liver. Timepoint: Before the intervention and 3 months after the administration of L-carnitine and curcumin in the intervention groups. Method of measurement: Ultrasonography and biochemical tests.